CD38 and Miyoshi myopathy: Interestingly, in those MM cell lines with heterogeneous CD38 surface expression, that is, with a CD38+ and a CD38−/low population (JJN3 and MM.1S), treatment with tinostamustine significantly increased the percentage of cells in the first population in the JJN3 cell line, and a similar tendency was observed for MM.1S cell line (Figure 1b).